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Abstract  
AIM: This study aimed to investigate genotype and allele frequencies of −174 (rs1800795) and 
−572 (rs1800796) IL-6 promoter gene polymorphisms in Egyptian patients with rheumatoid arthritis 
(RA) in comparison to control group.  
METHODS: The study was conducted on 198 Egyptian subjects (99 RA patients and 99 healthy 
control).The promoter region of the IL-6 gene was amplified by PCR using DNAs from patients and 
the controls, and their PCR products were digested by suitable enzymes.  
RESULTS: No statistical differences were found in −572G/C genotype (P = 0.177) or allele (P = 
0.147) frequencies between RA patients and controls. Significant differences were observed in 
−174G/C genotype (P ˂ 0.001) and allele (P ˂ 0.001) frequencies between RA patients and 
controls.  
CONCLUSION: A significant association of IL-6 −174G/C gene polymorphism and RA in Egyptian 
population was found with significantly higher frequencies of GC and CC genotypes and C allele in 
RA patients compared to controls. No association was found between IL-6 −572G/C gene 
polymorphism and RA. 
 
 
 
 
Introduction 
 
Rheumatoid arthritis (RA) is a multisystemic 
autoimmune inflammatory disease which has the 
prevalence of approximately 1% worldwide [1]. The 
interaction of genetic and environmental factors 
results in a cascade of immune reactions, which 
contributed to the pathogenesis of RA. The common 
manifestations of RA include synovitis, joint damage, 
and structural cartilage and bone damage. Also, 
uncontrolled active RA causes disability, diminished 
quality of life and number of extra-articular 
manifestations and comorbidities especially 
cardiovascular diseases which result in increased 
mortality [1, 2]. The aetiology and pathogenesis of RA 
are not clearly defined. However, some genetic 
factors were found to be contributed to RA 
susceptibility. HLA-DR loci were the most associated 
gene with RA susceptibility, although HLA-DR 
accounts only for approximately one-third of the 
genetic predisposition to RA [3]. Other genes also 
contributed to the genetic susceptibility to RA are 
cytokine genes such as TNFα, IL-1β and IL-6 genes 
which account for the relatively small additional role in 
RA genetic predisposition [3].
 
Interleukin 6 (IL-6) is one of the most studied 
pro-inflammatory cytokines that have the important 
role in the pathogenesis of RA. Serum and synovial 
fluid levels of IL-6 and soluble IL-6 receptors (sIL6R) 
were found to be elevated in patients with RA [4]. IL-6 
promotes the production of autoantibodies such as 
Rheumatoid Factor (RF) and Anti-Citrullinated Peptide 
Antibody (ACPA). In addition, it triggers the imbalance 
between Th17 cells and regulatory T cells (Treg). It 
also has a role in promoting synovial inflammation and 
cartilage and bone destruction as well as extra-
articular manifestation including cardiovascular, 
psychological and skeletal disorders [5]. Blockade of 
IL-6 activity with a soluble anti-IL-6 molecule 
tocilizumab has been found to decrease the disease 
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activity as well as the radiological progression of RA 
[6]. 
The human IL-6 gene is located on 
chromosome 7p21. Among the polymorphic sites 
described in the IL-6 gene promoter, there are two 
biallelic polymorphisms that may be associated with 
differences in cytokine production: −174G/C 
(rs1800795) and −572G/C (rs1800796). These 
polymorphisms consist of a single nucleotide change 
from guanine (G) to cytosine (C) at positions −174 and 
−572 in the promoter region, respectively [7]. IL-6 
promoter polymorphisms have been associated with 
susceptibility to RA, however, conflicting results were 
observed in different populations [8, 9]. 
 In the present study, we aimed to investigate 
genotype and allele frequencies of − 174 and −572 IL-
6 promoter gene polymorphisms in Egyptian patients 
with rheumatoid arthritis in comparison to control 
group. 
 
 
Subjects and Methods 
 
Study design 
This study was conducted on 99 Egyptian 
rheumatoid arthritis patients recruited from Internal 
Medicine and Rheumatology Clinic and Department of 
National Research Centre. The control group included 
99 healthy Egyptian subjects with no family histories 
of any autoimmune diseases. The RA patients were 
diagnosed according to American College of 
Rheumatology (ACR) criteria [10]. Full medical history 
was taken and thorough clinical examinations were 
performed for all patients. Laboratory investigations 
including erythrocyte sedimentation rate (ESR), C-
reactive protein (CRP), rheumatoid factor (RF) and 
anti-cyclic citrullinated peptide (anti-CCP) were 
performed. Also, Disease Activity Score (DAS) and 
Larsen score were calculated [11, 12]. Written 
informed consents were taken from patients and 
controls, and the study was approved by the National 
Research Centre ethics committee. 
 
Methods 
Blood collection and molecular analyses 
Venous blood samples were collected in 
EDTA tubes and stored at −80 °C, till DNA extraction. 
Genomic DNA extraction from white blood cells was 
carried out by QIA gene extraction Kit. 
  
Determination of IL-6 gene polymorphisms 
The final volume of PCR reaction mixture was 
25μl containing 40 ng genomic DNA, 10 picomoles 
each of forward and reverse primers at the 
concentration of 1X, 1X PCR master mixture.
 
To identify (−174) G/C polymorphism, the 
forward and the reverse primers were (5′-
TTGTCAAGACATGCCAAGTGCT-3′) and (5′-
GCCTCAGAGACATCTCCAGTCC-3′) and for (−572) 
G/C polymorphism, the forward and the reverse 
primers (5′-GGAGACGCCTTGAAGTAACTGC-3′) and 
(5′-GAGTTTCCTCTGACTCCATCGCAG-3′) were 
used. PCR amplification was carried out at 94°C for 5 
min followed by 30 cycles of denaturation at 94°C for 
30 sec, annealing at (57°C and 55°C for 30 sec for 
−174G/C & −572G/C respectively), extension at 72°C 
for 30 sec, and final extension at 72°C for 7 min. The 
PCR product of −174G/C was digested by Fast 
digestion of 5 units of Nla III enzyme at 37°C yielded 
G allele (244 + 133 + 11) bp and C allele (133 + 111 + 
56) bp products. For −572 G/C polymorphism, MbiI 
fast digestion restriction enzyme at 37°C was used 
yielded G allele (102, 61) bp and C allele (163) bp 
products. The obtained fragments' sizes were 
analysed on a 2% agarose gel [13].
 
 
Statistical Analysis 
Data was analysed using the Statistical 
Program for Social Science (SPSS) for Windows, 
Version 16.0 Chicago, SPSS Inc., 2007. The 
statistical data are reported as the mean ± SE, 
frequencies and percentages when appropriate. 
Comparison between two means and more than two 
means was done using student t-test and ANOVA test 
respectively. Chi-square and Fisher's exact test were 
used to examine the relationship between different 
variables. A statistical significance was considered 
when P ≤ 0.05 and Logistic regression was used for 
calculating the odds ratio.
 
  
 
Results 
 
Comparison between RA patients and 
controls in selected characteristics are shown in Table 
1. The female percent in RA patient was significantly 
higher than that in controls. The mean serum level of 
Anti- CCP of RA patients was significantly elevated to 
reach 25-fold that of controls. Also, the mean serum 
level of CRP of RA patients was significantly 
increased by 70% compared with controls. In addition, 
the mean serum levels of RF-IgA, IgG, and IgM were 
significantly elevated to reach (17-, 28-, and 34- fold, 
respectively) those of controls.
 
Table 2 show genotype and allele frequencies 
of −572G/C gene polymorphism in RA patients and 
controls. No statistical differences in genotype or 
allele frequencies between RA patients and controls 
were found. 
 Amr et al. Interleukin-6 Gene Polymorphisms in Egyptian Patients with Rheumatoid Arthritis 
______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                         3 
 
Table 1: Comparison between RA patients and controls in 
selected characteristics 
 
Variables 
RA patients Controls P value 
N = 99 N = 99  
    
Female (%) 90 (90.9%) 58 (58.59%) ˂ 0.001 
Anti- CCP, Mean ± SE 160.4 ± 16.47 6.52 ± 0.56 ˂0.001 
CRP (mg/L), Mean ± SE 24.39 ± 3.31 14.17 ± 3.15 ˂0.05 
RF IgA (IU/L), Mean ± SE 157.2 ± 29.15 9.37 ± 1.16 ˂0.001 
RF-IgG (IU/L), Mean ± SE
 354.8 ± 66.78 12.56 ± 1.45 ˂0.001 
RF IgM (IU/L), Mean ± SE 175.6 ± 35.66 5.15 ± 0.93 ˂0.001 
 
 
Table 3 show genotype and allele frequencies 
of −174G/C gene polymorphism in RA patients and 
controls. Regarding GC genotype, RA patients group 
showed higher frequency compared to control group 
(46.5% and 23.2% respectively) (P ˂ 0.001, OR = 
3.409).  
Table 2: The genotype and allele frequencies of −572G/C 
polymorphism in RA patients group and controls 
 
Genotype 
RA patient Control 
P value 
Odd ratio 
(95% CI) 
N = 99 N = 99 
n (%) n (%) 
GG 26 (26.3) 36 (36.4)  1.000 (Reference) 
GC 64 (64.6) 58 (58.6) 0.177 1.528 (0.824-2.832) 
CC 9 (9.1) 5 (5.1) 0.130 2.492 (0.748-8.308) 
Allele     
G 116 (58.6) 130 (65.7) 
0.147 1.351 (0.899-2.031) 
C 82 (41.4) 68 (34.3) 
 
 
Also, there was higher frequency of CC 
genotype in RA group (9.1%) compared to control 
group (1%) (P = 0.001, OR = 15.341). In accordance 
to allele frequencies, C allele was found in higher 
frequency in RA patients group (32.3%) compared 
with controls (12.6%) (P ˂ 0.001, OR = 3.305). 
Table 3: The genotype and allele frequencies of −174G/C 
polymorphism in RA patients group and controls 
Genotype 
RA patient Control P value Odd ratio 
N = 99 N = 99  (95% CI) 
n (%) n (%)   
GG 44 (44.4) 75 (75.8)  1.000 (Reference) 
GC 46 (46.5) 23 (23.2) 0.000 3.409(1.827-6.361) 
CC 9 (9.1) 1 (1) 0.001 15.341(1.88-125.181) 
Allele     
G 134 (67.7) 173 (87.4) 
0.000 3.305(1.976-5.528) 
C 64 (32.3) 25 (12.6)  
 
 
 
Discussion 
 
Rheumatoid arthritis is a chronic inflammatory 
disease resulting from a cascade of immunological 
reactions. IL-6 is an acute phase cytokine contributes 
to host defence against infectious agents and tissue 
injuries by inducing immunological and hematopoietic 
responses. However, uncontrolled persistent 
production of IL-6 may lead to the development of 
several immune-mediated diseases. Thus, 
dysregulated persistent production of IL-6 has a 
crucial role in the pathogenesis of RA [14]. 
Regarding IL-6 −572G/C gene polymorphism, 
our study identified that the GC genotype is the most 
frequently genotype observed in both RA patients and 
controls and no significant differences were observed 
in the genotypes and alleles frequencies between RA 
patients group and controls (Table 2). Our results 
were in agreement with Zavaleta-Muñiz et al., 2013 
who found no significant differences in allele or 
genotype frequencies of this polymorphism between 
RA and controls. But in contrast to our results, they 
found that the GG genotype was the most frequently 
observed genotype in the Mexican mestizo population 
among patients with RA and healthy controls (54% 
and 60.8% respectively) [7]. Also, Li et al., 2014a 
observed no association for IL-6 −572G/C gene 
polymorphism and RA in Chines Han population. And 
in agreement with our results, they observed that GC 
genotype was the most frequent genotype found in 
both RA patients and controls (48.8% and 45.9% 
respectively) [9]. Our findings also were in agreement 
with other studies in which they found no relationship 
between IL-6 −572G/C gene polymorphism and RA in 
different populations such as Taiwan and Turkish 
population [8, 15]. However, in contrast to our results 
Lo et al., 2008 found that the most frequent genotype 
in RA patients was CC genotype (60.8%) which was 
similar to the genotype distribution of the controls [15]. 
Regarding IL-6 −174G/C gene polymorphism, 
our results found that both GC and CC genotypes 
were associated with RA risk, and C allele increased 
the susceptibility of RA in the studied Egyptian 
population. Our results came in agreement with Li et 
al., 2014a who observed a statistically significant 
association for IL-6 −174G/C gene polymorphism and 
RA. They identified higher frequency of C allele in RA 
patients compared to controls (2.1% versus 0.5%) OR 
= 4.823 and P = 0.016 [9]. 
Moreover, in agreement with our findings, Li 
et al., 2014b identified that the frequency of CC 
genotype and C allele were significantly higher in RA 
patients compared to controls (2% versus 0.25% and 
10.24% versus 0.88% respectively) (P ˂ 0.001). Their 
results also showed a significantly increased risk of 
RA for the CC genotype and the C allele of IL-6 
−174G/C gene polymorphism in Chines population 
[16]. 
On the other hand, our results were against 
different studies in which they found no differences in 
allele or genotype frequencies of IL-6 −174G/C gene 
polymorphism between RA and controls in a different 
population such as Mexican and Turkish populations 
[7, 8]. The controversy of results may be due to 
different origin or ethnicity.
 
IL-6 is a pro-inflammatory cytokine that has 
different pleiotropic activities including induction of 
acute phase proteins and stimulation of T and B cells, 
synoviocytes and osteoclasts. These inflammatory 
reactions result in cartilage and bone damage as well 
as other systemic manifestations [17]. Previous study 
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observed that polymorphisms in the promoter region 
of the IL-6 gene may be responsible for changes in 
the transcriptional activity and the expression of IL-6 
in serum and synovial tissue, which could, in turn, 
lead to greater inflammation and thus affect the 
clinical status of RA patients [18]. In other study, 
patients with the −174G allele showed higher rates of 
progression of erosive damage, although it was not 
statistically significant even in the presence of longer 
disease duration at baseline [19]. 
In conclusion, this study revealed a significant 
association of IL-6 −174G/C gene polymorphism and 
RA in Egyptian population with significantly higher 
frequencies of GC and CC genotypes and C allele in 
RA patients compared to controls. No association 
between IL-6 −572G/C gene polymorphism and RA 
was found in our cohort RA patients. Also, no 
correlations between different genotypes and all 
measured biomarkers were observed. 
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